NECT trial: more than a small victory over sleeping sickness

The Lancet

Volumn 374, Issue 9683, 2009, Pages 7-9

  Opigo, Jimmy ^a   Woodrow, Charles ^b,c  

^a Unit of Epidemiology and Disease Control   (Belgium)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

EFLORNITHINE; MELARSOPROL; NIFURTIMOX; PENTAMIDINE;

AFRICAN TRYPANOSOMIASIS; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FOLLOW UP; HUMAN; LUMBAR PUNCTURE; METHODOLOGY; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME; TRYPANOSOMA; UNSPECIFIED SIDE EFFECT; WORLD HEALTH ORGANIZATION;

EID: 67649659931     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)61163-6     Document Type: Note

References (12)

1. Robays J., Nyamowala G., Sese C., et al. High failure rates of melarsoprol for sleeping sickness, Democratic Republic of Congo. Emerg Infect Dis 14 (2008) 966-967
2. Balasegaram M., Young H., Chappuis F., et al. Effectiveness of melarsoprol and eflornithine as first-line regimens for gambiense sleeping sickness in nine Médecins Sans Frontières programmes. Trans R Soc Trop Med Hyg 103 (2009) 280-290
3. Priotto G., Pinoges L., Fursa I.B., et al. Safety and effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: cohort study. BMJ 336 (2008) 705-708
4. Pepin J., Khonde N., Maiso F., et al. Short-course eflornithine in Gambian trypanosomiasis: a multicentre randomized controlled trial. Bull World Health Organ 78 (2000) 1284-1295
5. Bisser S., N'Siesi F.X., Lejon V., et al. Equivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei gambiense sleeping sickness. J Infect Dis 195 (2007) 322-329
6. Priotto G., Fogg C., Balasegaram M., et al. Three drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Uganda. PLoS Clin Trials 1 (2006) e39
7. Priotto G., Kasparian S., Ngouama D., et al. Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo. Clin Infect Dis 45 (2007) 1435-1442
8. Checchi F., Piola P., Ayikoru H., et al. Nifurtimox plus eflornithine for late-stage sleeping sickness in Uganda: a case series. PLoS Negl Trop Dis 1 (2007) e64
9. Priotto G., Kasparian S., Mutombo W., et al. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet (2009) 10.1016/S0140-6736(09)61117-X published online June 25.
10. Stepniewska K., and White N.J. Some considerations in the design and interpretation of antimalarial drug trials in uncomplicated falciparum malaria. Malar J 5 (2006) 127
11. Piaggio G., Elbourne D.R., Altman D.G., et al. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA 295 (2006) 1152-1160
12. BBC World News Film. Survival-the deadliest disease (Oct 11, 2008). http://bbcworldnews.survival.tv/documentaries/sleeping_sickness.php (accessed June 22, 2009).